HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hashizume, H. Articles by Tokura, Y. Search for Related Content PubMed PubMed Citation Articles by Hashizume, H. Articles by Tokura, Y.

Characterization of Drug-Specific T Cells in Phenobarbital- Induced Eruption

Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan

Phenobarbital has a high potential to elicit adverse reactions including severe skin eruptions and systemic involvements among the worldwide-prescribed drugs. Although phenobarbital hypersensitivity is thought to be mediated by T cells specific to the drug, its precise mechanism remains not fully elucidated. To characterize T cells reactive with phenobarbital, we generated drug-specific T cell clones and lines from PBMCs of patients with phenobarbital hypersensitivity showing various degrees of cutaneous and extracutaneous involvements. Although the TCR V repertoire and phenotype in the T cell clones/T cell lines were heterogeneous among the patients, V13.1⁺ and V5.1⁺ clones or lines were raised from the individuals examined who possessed different HLA haplotypes. Histopathological examination suggested that V5.1⁺CD8⁺ T cells and V13.1⁺ T cells played a role in cutaneous and extracutaneous involvements, respectively. A V13.1⁺CD4⁺ clone was found to proliferate in response to the Ag with processing-impaired, fixed APCs. Most of the clones and lines belonged to the Th2 phenotype, producing IL-4 and IL-5 but not IFN- upon phenobarbital stimulation. Clones/lines with Th1 or Th0 phenotypes also constituted minor populations. These observations clearly indicate the heterogeneity and a marked individual deviation of reactive T cell subsets among the patients in terms of CD4/8 phenotype, V repertoire, Ag recognition pattern, and cytokine production; and thus provide evidence whereby each pathogenic T cell subset contributes to special elements of clinical presentation.

This article has been cited by other articles:

				H. Hashizume, N. Seo, T. Ito, M. Takigawa, and H. Yagi Promiscuous Interaction between Gold-Specific T Cells and APCs in Gold Allergy J. Immunol., December 1, 2008; 181(11): 8096 - 8102. [Abstract] [Full Text] [PDF]

				L. J. Hirsch, H. Arif, E. A. Nahm, R. Buchsbaum, S. R. Resor Jr, and C. W. Bazil Cross-sensitivity of skin rashes with antiepileptic drug use Neurology, November 4, 2008; 71(19): 1527 - 1534. [Abstract] [Full Text] [PDF]

				H. Yagi, H. Hashizume, T. Horibe, Y. Yoshinari, M. Hata, A. Ohshima, T. Ito, M. Takigawa, A. Shibaki, H. Shimizu, et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous Peptide immunization. Cancer Res., October 15, 2006; 66(20): 10136 - 10144. [Abstract] [Full Text] [PDF]

				D. J. Naisbitt, J. Farrell, P. J. Chamberlain, J. E. Hopkins, N. G. Berry, M. Pirmohamed, and B. K. Park Characterization of the T-Cell Response in a Patient with Phenindione Hypersensitivity J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1058 - 1065. [Abstract] [Full Text] [PDF]

				S. Nierkens, L. Nieuwenhuijsen, M. Thomas, and R. Pieters Evaluation of the Use of Reporter Antigens in an Auricular Lymph Node Assay to Assess the Immunosensitizing Potential of Drugs Toxicol. Sci., May 1, 2004; 79(1): 90 - 97. [Abstract] [Full Text] [PDF]

				J. Farrell, D. J. Naisbitt, N. S. Drummond, J. P. H. Depta, F. J. Vilar, M. Pirmohamed, and B. K. Park Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 229 - 237. [Abstract] [Full Text] [PDF]